Author:
Nevzglyadova O. V.,Mikhailova E. V.,Soidla T. R.
Reference119 articles.
1. Adem, K., Shanti, A., Srivastava, A., Homouz, D., Thomas, S.A., Khair, M., Stefanini, C., Chan, V., Kim, T.Y., and Lee, S., Linking Alzheimer’s disease and type 2 diabetes: characterization and inhibition of cytotoxic Aβ and IAPP hetero-aggregates, Front. Mol. Biosci., 2022, vol. 9, p. 842582. https://doi.org/10.3389/fmolb.2022.842582
2. Agarwal, A., Arora, L., Rai, S.K., Avni, A., and Mukhopadhyay, S., Spatiotemporal modulations in heterotypic condensates of prion and α-synuclein control phase transitions and amyloid conversion, Nat. Commun., 2022, vol. 13, p. 1. https://doi.org/10.1038/s41467-022-28797-5
3. Alam, P., Bousset, L., Melki, R., and Otzen, D.E., α-Synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities, J. Neurochem., 2019, vol. 150, p. 522. https://doi.org/10.1111/jnc.14808
4. Ashrafian, H., Zadeh, E.H., and Khan, R.H.,Review on Alzheimer’s disease: inhibition of amyloid beta and tau tangle formation, Int. J. Biol. Macromol., 2021, vol. 167, p. 382. https://doi.org/10.1016/j.ijbiomac.2020.11.192
5. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., and Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies, Am. J. Pathol., 1998, vol. 152, p. 879.